Patented medicine and affordability – Opinion – The Hindu
0
India’s ongoing efforts at safeguarding its intellectual property rights (IPRs) have been facing challenges from different directions.
In the heavily contested area of pharmaceutical patents, the Supreme Court, in an important ruling, stalled a last-ditch effort by German drugmaker Bayer to block the sale of a cheaper generic version of cancer drug Nexavar.
Upholding earlier rulings, the apex court stymied global drugmakers’ efforts to hold on to exclusivity on high priced drugs.
Domestic generic drug maker Natco was granted a patent in 2012 to sell a generic version of Nexavar at Rs.8,800 for a month’s dose, a fraction of Bayer’s price of Rs.2.80 lakh.
Read more – The Hindu